2-[(1S)-1-chloro-3-methylbutyl]-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole | 87304-47-0

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-[(1S)-1-chloro-3-methylbutyl]-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole
• 英文别名: (+)-pinanediol (R)-1-chloro-3-methylbutane-1-boronate；(1S,2S,6R,8S)-4-((1R)-1-chloro-3-methylbutyl)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0(2,6)]decane；(1R)-(S)-pinanediol 1-chloro-3-methylbutane-1-boronate；(3aS,4S,6S,7aR)-2-((R)-1-Chloro-3-methylbutyl)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole；(1S,2S,6R,8S)-4-[(1R)-1-chloro-3-methylbutyl]-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decane
• CAS: 87304-47-0
• 化学式: C₁₅H₂₆BClO₂
• 分子量: 284.634
• InChiKey: DEIWLENJRMQSPT-AIUMHDJVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.91
• 重原子数：
  19.0
• 可旋转键数：
  3.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.46
• 氢给体数：
  0.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  2-[(1S)-1-chloro-3-methylbutyl]-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole 在 双(三甲基硅烷基)氨基钾 、 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 为溶剂， 以51%的产率得到(R)-1-氨基-3-甲基丁基硼酸蒎烷二醇酯盐酸盐
  参考文献：
  名称：

  Expanding the scope of PNA-encoded libraries: divergent synthesis of libraries targeting cysteine, serine and metallo-proteases as well as tyrosine phosphatases

  摘要：

  Seven PNA-encoded combinatorial libraries targeting proteases and phosphatases with covalent reversible and irreversible mechanism-based inhibitors were prepared. The libraries were synthesized using modified PNA monomers, which dramatically increase the water solubility of the libraries in biologically relevant buffers. The libraries were shown to selectively inhibit targeted enzymes. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2007.03.033
• 作为产物：
  描述：

  (1S,2S,3R,5S)-(+)-2,3-蒎烷二醇 在 正丁基锂 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 9.66h， 生成 2-[(1S)-1-chloro-3-methylbutyl]-(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborole
  参考文献：
  名称：

  由αα-和αβ-氨基酸构建的新型二肽基硼酸蛋白酶体抑制剂的设计，合成和对接研究

  摘要：

  设计并合成了一系列由αα-和αβ-氨基酸构建的新型二肽基硼酸蛋白酶体抑制剂。通过1 H NMR，13 C NMR，LC-MS和HRMS阐明了它们的结构。评价这些化合物对人蛋白酶体的β5亚基抑制活性。结果表明，由αα-氨基酸组成的二肽基硼酸抑制剂的活性与硼替佐米相同。有趣的是，那些衍生自αβ-氨基酸的酶的活性完全丧失了。在所有抑制剂中，化合物22（IC 50  = 4.82 nM）对蛋白酶体活性的抑制作用最强。化合物22还是对三种具有IC 50的MM细胞系最有活性的在抑制细胞生长试验中，其值小于5 nM。分子对接研究表明，22个蛋白非常适合蛋白酶体的β5亚基活性口袋。

  DOI：

  10.1016/j.bmcl.2016.03.007

文献信息

• Discovery of a Potent, Selective, and Orally Active Proteasome Inhibitor for the Treatment of Cancer
  作者：Bruce D. Dorsey、Mohamed Iqbal、Sankar Chatterjee、Ernesto Menta、Raffaella Bernardini、Alberto Bernareggi、Paolo G. Cassarà、Germano D’Arasmo、Edmondo Ferretti、Sergio De Munari、Ambrogio Oliva、Gabriella Pezzoni、Cecilia Allievi、Ivan Strepponi、Bruce Ruggeri、Mark A. Ator、Michael Williams、John P. Mallamo

  DOI：10.1021/jm7010589

  日期：2008.2.1

  malignant cells. The successful development of the 20S human proteasome inhibitor bortezomib for the treatment of relapsed and refractory multiple myeloma has established this targeted intervention as an effective therapeutic strategy. Herein, the potent, selective, and orally bioavailable threonine-derived 20S human proteasome inhibitor that has been advanced to preclinical development, [(1R)-1-[[(2 S,3

  泛素-蛋白酶体途径在调节细胞蛋白的产生和破坏中起关键作用。这些途径介导增殖和细胞存活，特别是在恶性细胞中。用于治疗复发性和难治性多发性骨髓瘤的20S人类蛋白酶体抑制剂硼替佐米的成功开发已将这种靶向干预确立为有效的治疗策略。在本文中，有效，选择性和口服生物利用的苏氨酸来源的20S人蛋白酶体抑制剂已被推进到临床前开发，[（1R）-1-[[（2 S，3 R）-3-hydroxy-2-[[公开了6-苯基吡啶-2-羰基氨基] -1-氧丁基]氨基] -3-甲基丁基]硼酸20（CEP-18770）。
• Mixing of peptides and electrophilic traps gives rise to potent, broad-spectrum proteasome inhibitors
  作者：Martijn Verdoes、Bogdan I. Florea、Wouter A. van der Linden、Didier Renou、Adrianus M. C. H. van den Nieuwendijk、Gijs A. van der Marel、Herman S. Overkleeft

  DOI：10.1039/b702268a

  日期：——

  The synthesis and evaluation of hybrid proteasome inhibitors that contain structural elements of the known inhibitors bortezomib, epoxomicin and peptide vinyl sulfones is described. From the panel of 15 inhibitors some structure activity relationships can be deduced with regard to inhibitory activity in relation to peptide recognition element, inhibitor size and nature of the electrophilic trap. Further

  描述了杂合蛋白酶体抑制剂的合成和评估，这些蛋白酶体抑制剂包含已知的硼替佐米，环己霉素和肽乙烯基砜抑制剂的结构元素。从15种抑制剂的组中，可以推断出与肽识别元件，抑制剂大小和亲电子阱性质有关的抑制活性方面的一些结构活性关系。此外，该组包含迄今为止报道的最有效的基于肽的泛蛋白酶体抑制剂之一。
• [EN] SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS<br/>[FR] SYNTHESE D'ESTER BORIQUE ET DE COMPOSES ACIDES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2005097809A3

  公开（公告）日：2006-02-16
• Further characterization of a putative serine protease contributing to the γ-secretase cleavage of β-amyloid precursor protein
  作者：Marine Peuchmaur、Marie-Agnès Lacour、Jean Sévalle、Vincent Lisowski、Youness Touati-Jallabe、Fabien Rodier、Jean Martinez、Frédéric Checler、Jean-François Hernandez

  DOI：10.1016/j.bmc.2012.11.045

  日期：2013.2

  The 3-alkoxy-7-amino-4-chloro-isocoumarins JLK-6 and JLK-2 have been shown to markedly reduce the production of Amyloid beta-peptide (A beta) by Amyloid-beta Precursor Protein (APP) expressing HEK293 cells by affecting the gamma-secretase cleavage of APP, with no effect on the cleavage of the Notch receptor. This suggested that these compounds do not directly inhibit the presenilin-dependent gamma-secretase complex but more likely interfere with an upstream target involved in gamma-secretase-associated pathway. The mechanism of action of these compounds is unknown and there are high fundamental and therapeutical interests to unravel their target. Isocoumarin compounds were previously shown to behave as potent mechanism-based irreversible inhibitors of serine proteases, suggesting that the JLK-directed target could belong to such enzyme family. To get further insight into structure-activity relationships and to develop more potent isocoumarin derivatives, we have synthesized and evaluated a series of isocoumarin analogues with modifications at positions 3, 4 and 7. In particular, the 7-amino group was substituted with either acyl, urethane, alkyl or aryl groups, which could represent additional interaction sites. Altogether, the results highlighted the essential integrity of the 3-alkoxy-7-amino-4-chloro-isocoumarin scaffold for A beta-lowering activity and supported the involvement of a seri ne protease, or may be more generally, a serine hydrolase. The newly reported 7-N-alkyl series produced the most active compounds with an IC50 between 10 and 30 mu M. Finally, we also explored peptide boronates, a series of reversible serine protease inhibitors, previously shown to also lower cellular A beta production. The presented data suggested they could act on the same target or interfere with the same pathway as isocoumarins derivatives. (C) 2012 Elsevier Ltd. All rights reserved.
• Diastereoselection in reactions of pinanediol dichloromethaneboronate
  作者：David J. S. Tsai、Pradipta K. Jesthi、Donald S. Matteson

  DOI：10.1021/om50005a010

  日期：1983.11